The Real Price of AbbVie Stock Is Cheaper Than You Think
The sticker shock on the pharma giant’s shares fades once you look at what investors are paying for the earnings expected just two years from now.
At a glance, AbbVie (ABBV) stock looks expensive. Trading near its 52-week high, the shares command a price-to-earnings multiple of about 55.5 times the last twelve months of adjusted earnings. For many investors, that’s where the analysis stops. But it shouldn’t.
That same stock price, when measured against the earnings analysts expect the company to generate by 2027, represents a multiple of just 16.1 times. That is a steep 71% discount from today’s trailing multiple. This is the forward valuation discount: the way the price you pay effectively falls on its own as a company’s earnings grow into the stock price. A patient holder is not buying the stock at 55.5 times earnings; they are effectively buying 2027’s earnings at a far more conventional 16.1 times multiple.
Is The Growth That Creates The Discount Believable?
The honest question is never the price tag, but whether the growth that produces this discount will actually arrive. Here, the story gets interesting. The discount isn’t based on a heroic leap in sales. Consensus forecasts call for revenue to grow about 7.7% a year, which is actually a step down from the 9.5% growth AbbVie delivered over the last twelve months and the 12.4% it posted in its most recent quarter. Strong performance from its immunology blockbusters, Skyrizi and Rinvoq, continues to drive the top line.
The real engine of the discount is a significant, one-year recovery in earnings. Analysts expect earnings per share to jump from about $14.05 this year to $16.46 in 2027. That starting point for 2026 is credible, as it sits squarely within the $13.90 to $14.10 per share guidance that management itself has provided. The expected earnings jump is largely a story of expanding profit margins. Management forecasts a full-year adjusted operating margin of approximately 48% for 2026, a material improvement from the 33% reported over the last year, partly as significant one-time R&D expenses from the first quarter are not expected to repeat.
And AbbVie is far from alone: which 10 S&P 500 stocks carry the biggest hidden forward discount? Our rankings sort the entire index by how little you are really paying for each name’s growth once the out-year earnings land.
The Margin of Safety and the Reward
A stock priced for this kind of growth can be volatile. In past market shocks, AbbVie has fallen as much as 31%, a reminder that patience is a prerequisite. The forward discount is your reward for that patience, acting as a margin of safety.
If the growth arrives but the stock price never moves, you would simply own a company in 2027 trading at about 16.1 times earnings. That proves you didn’t overpay, but it doesn’t produce a gain. The actual reward comes only if the market continues to value AbbVie at a premium as those higher earnings materialize. For perspective, if the multiple were to settle at about 35.8 times, roughly halfway between today’s level and that 16.1-times floor, the stock would be about 122% higher. The engine behind ABBV stock has real parts, and understanding them is key to seeing the potential path forward.
What You’re Really Paying For
The premium you see today is not the price you are really paying. On the earnings analysts expect two years out, that same price is an ordinary multiple. This suggests that even if the stock stalls, a long-term holder has not overpaid for the growth embedded in the price. The upside is conditional: if the market keeps paying anything near today’s multiple as those earnings actually arrive, the share price compounds with them.
The single most important metric to watch is the adjusted operating margin. If AbbVie hits its full-year target of 48%, it will be a clear sign that the earnings recovery powering this forward discount is right on track.
Own The Growth Without Overpaying
Whether you already hold AbbVie or you are weighing it now, the appeal is not that the stock is secretly cheap today. It is that you are not overpaying for the growth: on the earnings analysts expect two years out, you are paying an ordinary multiple, even if the price never moves.
The upside sits on top of that. If the market keeps paying anything close to today’s multiple as those earnings actually arrive, the price compounds with them. The one catch is that it all rides on a single company’s numbers coming through. And if it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV covers that sector, though that still leaves you riding a single slice of the market. That is why the Trefis High Quality (HQ) Portfolio does not lean on any single name: it uses this same valuation-discount discipline to size a measured allocation to strong growth like this, inside a diversified set of 30 high-conviction stocks, re-balanced as the estimates change and with a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.